

First quarter January – March 2013

- Net sales amounted to SEK 63.4 (64.3) million, down 1.4 percent. Changes in the USD and EUR exchange rates had a negative impact of SEK 2.0 million on net sales.
- Operating profit totaled SEK 0.5 million (4.5).
- Loss after tax was SEK 1.7 million (profit 2.1).
- Loss per share amounted to SEK 0.36 (profit: 0.45).

Key events during the first quarter 2013

Higher investments in emerging markets

A subsidiary was established in Mexico to increase focus on the Latin American market. The subsidiary will enable Boule to meet demand for the company's products with greater efficiency and provide better support to distributors in the region.

Boule also established a sales office in Dubai. This will enable closer contact with the company's customers in the attractive emerging markets in the Middle East and Africa.

Key events following the end of the reporting period

New premises for expansion of the OEM business

Boule continues to invest in the development of products for industrial customers, known as OEM products. To meet the predicted increase in the

production of these products, a new lease was signed in early April.

Financial summary

Key figures	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012	Rolling 12 months
Net sales, SEK million	63.4	64.3	275.3	274.5
Net sales growth, %	-1.4	1.3	11.8	11.0
Gross profit, SEK million	27.9	28.3	123.5	123.2
Gross margin, %	44.0	44.0	44.9	44.9
EBITDA, SEK million	1.4	5.0	23.5	19.9
EBITDA margin, %	2.2	7.8	8.5	7.2
Operating profit/loss, SEK million	0.5	4.5	20.4	16.3
Operating margin, %	0.8	7.0	7.4	5.9
Net profit/loss, SEK million	-1.7	2.1	11.0	7.1
Earnings/loss per share, SEK	-0.36	0.45	2.33	1.52
Cash flow from operating activities per share, SEK	0.31	0.61	2.20	2.02
Return on equity, % ¹⁾	3.7	4.7	5.6	3.7
Equity per share, SEK	42.1	40.8	42.4	42.1
Equity/assets ratio, %	70	80	73	70

1) Rolling 12 months

Comments from the CEO

As previously communicated, the buying behavior of our customers varies considerably, which always makes individual quarters difficult to compare. This also applies to the first quarter of 2013.

In our largest market, North America, sales of human systems declined due partly to starting the year with changes in our sales and support organization. However, sales of veterinary systems rose compared with the preceding year. Sales declined in Latin America due to inefficient market penetration. This trend was already evident in 2012. Since opening the sales office in Mexico in January 2013, we have worked intensively to evaluate new and existing distribution channels in the region with the intention of capitalizing on this market's major potential.

Sales in the EU were also weak during the first quarter, but continued to rise in Eastern Europe, particularly in Russia. In Asia, several countries contributed to an increase during the period, while sales in China showed a weak trend, partly due to inventory accumulations by distributors during the preceding quarter and more intensive competition from 5-part systems. However, market performances in Africa and the Middle East were strong and we are now beginning to see the results of our long-term efforts to penetrate these markets. The establishment of a local sales office in Dubai proceeded according to plan and entails a significant boost for our efforts in this part of the world.

In conjunction with the production of prototype instruments and cassettes for the POC system, in preparation for the planned clinical trials, we did not achieve the level of robustness required. We will now solve these problems before confirming a revised launch plan. This also entails that we can devote more attention to other areas of the business during the period, such as OEM production, where several interesting projects are currently taking place.

To summarize, the first quarter opened somewhat weaker than expected, but from what we know about our markets we remain convinced that ongoing investments in our core business will continue to drive high growth and contribute to the achievement of Boule's growth and profitability objectives.

Ernst Westman, President and CEO, Boule Diagnostics AB

Operations

The Group's operations are focused on complete blood counts – hematology, a field of medicine concerned with the study of blood, blood diseases and other diseases that can be diagnosed using a complete blood count (CBC). If a physician meets a patient with an unclear clinical presentation, an automated system for complete blood counts can be used to analyze the patient's blood. Deviations from the reference ranges for the three different blood cells in human blood can provide a unique and comprehensive assessment of health status and indicate several different illnesses.

Today, the CBC is one of the most common diagnostic tests performed by clinical laboratories around the world and analyses are conducted in both human and veterinary diagnostics. A total of 1.2 billion blood analyses are carried out per year and the estimated value of the hematology market is SEK 19 billion. The value of Boule's market segment (decentralized diagnostics) is about SEK 4.8 billion. Boule's global market share is approximately 6 percent.

Business model

The company's business model is based on sales of cell-counting instruments in the global hematology market and then sharing the recurring revenue streams through sales of reagents, controls, calibrators and service/support for the instruments. The company's instruments are locked to its proprietary reagents, providing more accurate analysis results and recurring revenue over the lifespan of the instruments.

A key component of the business model is also to sell reagents, calibrators and controls to OEM customers, meaning customers that sell the products under their own brand.

Products

The company's product portfolio comprises a number of product families/brands, of which CDS,

Medonic and Swelab are the most important. The instruments come in a range of designs and primarily target the human diagnostics market but are also sold to the veterinary market.

The products are currently marketed via a well-developed distribution network in more than 100 countries, and directly in a few key markets.

The company has also been conducting a major development project over the past few years to produce a unique product in Point-Of-Care (POC) diagnostics, which is an advanced system for medical testing at or near the site of patient care that is more convenient for the customer.

Financial objectives

Boule aims to achieve:

- annual average sales growth exceeding 10 percent per year over a five-year period,
- an annual EBITDA margin that exceeds 15 percent,
- an equity/assets ratio of 30-50 percent.

Financial objectives	2013 ²⁾		2012 ¹⁾	2011 ¹⁾	2010 ¹⁾
	Mar	Jan-Mar	Jan-Dec	Jan-Dec	Jan-Dec
Sales growth, %	1.0	-1.4	11.1	12.6	12.6
EBITDA margin, %	2.5	2.2	8.5	8.1	10.1
Equity/assets ratio, %	70	70	73	71	63

1) Sales growth, 5-year average, %
 2) Sales growth, compared with 2011

The Group's development

Revenue

Net sales for January-March 2013 totaled SEK 63.4 million (64.3), down 1.4 percent. Changes in the USD and EUR exchange rates had a negative impact of SEK 2.0 million on net sales. The buying behavior of our customers varies, which always makes individual quarters difficult to compare.

Instrument sales accounted for 47 percent (46) of net sales for January-March 2013, consumables for 43 percent (47) and other sales for 10 percent (7).

Distributed by region for January-March 2013, North America accounted for 43 percent (45) of net sales, Europe for 21 percent (22), Asia for 22 percent (19), Latin America for 3 percent (6), Africa for 4 percent (3) and the Middle East for 7 percent (5).

Sales per region and product

Net sales distributed by region MSEK	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012	Rolling 12 months
Western Europe	6.9	8.9	34.3	32.3
Eastern Europe	6.2	5.4	30.7	31.5
North America	27.1	29.1	115.7	113.8
Latin America	1.9	3.8	15.4	13.5
Asia	14.2	12.0	56.8	59.0
Africa	2.5	2.1	11.3	11.7
Middle East	4.4	3.0	10.8	12.2
Oceania	0.2	0.0	0.3	0.5
Total	63.4	64.3	275.3	274.5

Net sales distributed by products MSEK	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012	Rolling 12 months
Instruments	30.1	29.6	126.7	127.3
Consumables	27.3	29.7	125.2	122.8
Other	6.0	5.0	23.4	24.4
Total	63.4	64.3	275.3	274.5

Expenses

Operating expenses amounted to SEK 27.2 million (22.9) during January-March 2013. The increase was due primarily to higher costs for marketing and sales activities, and for research and development.

The research and development expenses charged to earnings in January-March 2013 totaled SEK 6.4 million (4.8), corresponding to 10.1 percent (7.4) of net sales. Research and development expenses of SEK 7.6 million (6.5) were capitalized during January-March 2013.

Capitalized expenses were primarily attributable to development of the POC system, while the development expenses charged against earnings derive from the improvement and maintenance of existing products.

The net of other operating revenues and other operating expenses during January-March 2013 was an expense of SEK 0.2 million (expense: 0.9).

The net primarily comprised realized and unrealized exchange-rate losses from operations.

Profit

Gross profit for January-March 2013 declined to SEK 28.0 million (28.3). Operating profit for January-March 2013 amounted to SEK 0.5 million (4.5).

The decrease in operating profit was primarily due to higher investments in sales and development and non-recurring costs of SEK 1.2 million during the first quarter of 2013.

In the January-March 2013 period, net financial items amounted to an expense of SEK 0.7 million (expense: 0.1). To date in 2013, interest expenses have increased due to the company's increased utilization of overdraft facilities.

In the January-March 2013 period, earnings before tax amounted to a loss of SEK 0.2 million (profit: 4.4).

Tax expenses were primarily attributable to the change in deferred tax liabilities on capitalized development expenditure.

Loss for the period was SEK 1.7 million (profit: 4.7).

Investments and cash flow

Cash flow from operating activities totaled SEK 1.4 million (2.9) during January-March 2013.

Changes in working capital amounted to SEK 0.2 million (neg: 2.4).

During January-March 2013, net investments totaled SEK 8.6 million (8.4). Investments for January-March 2013 are in line with the year-on-year period, but the distribution is different.

Capital requirements for the period totaling SEK 7.2 million were financed by increasing the utilization of both overdraft facilities and the company's own liquid funds.

In January-March 2013, cash flow for the period amounted to an expense of SEK 0.05 million (expense: 32.1). Cash and cash equivalents on March 31, 2013 amounted to SEK 15.8 million (21.2).

Available cash and cash equivalents for the Group, including unutilized credit facilities, amounted to SEK 36.3 million (58.3) on March 31, 2013.

Equity and liabilities

Group equity on March 31, 2013 totaled SEK 198.0 million (192.0).

The Group's equity/assets ratio was 70 percent (80) on March 31, 2013.

Interest-bearing liabilities, predominantly due to the utilization of overdraft facilities, amounted to SEK 28.5 million (5.1) on March 31, 2013. Interest-bearing liabilities comprise SEK 0.7 million (1.2) in long-term liabilities and SEK 27.8 million (0.2) in current liabilities.

As of March 31, 2013, other non-interest-bearing current liabilities and accounts payable amounted to SEK 43.7 million (38.5).

The increase in deferred tax liabilities was due to the change in deferred tax liabilities on capitalized development expenditure.

On December 31, 2012, deferred tax assets and deferred tax liabilities amounted to SEK 1.4 million

(1.4) and SEK 13.0 million (5.5), respectively.

Significant risks and uncertainties

The Group's operations are subject to a number of risks and uncertainties.

There is always a risk of competitors offering more efficient and better products than Boule and that the customer base will shrink as a result. Faulty, delayed delivery or non-delivery from the company's suppliers could in turn also lead to delayed, defective or faulty delivery by the company.

There is no guarantee that the company's operations will not be subjected to restrictions by government authorities or that it will obtain requisite regulatory approvals in the future.

The company is also exposed to the risk that it could lose its ability to develop products, or that its products cannot be launched according to schedule or that the market reception is poorer than expected. These risks could result in lower sales and thus adversely affect the company's earnings.

Parent Company

Boule Diagnostics AB (publ), Corporate Registration Number 556535-0252, is a Swedish corporation with its registered address in Stockholm. The address of its headquarters is Västberga Allé 32, Box 42056, SE-126 13 Stockholm, Sweden.

The Parent Company's revenues derive from Group-wide services. Risks and uncertainties in the Parent Company indirectly match those of the Group.

Administrative costs were somewhat higher than in the preceding year, due primarily to higher staffing compared with the year-on-year period. Receivables from Group companies primarily pertain to receivables from the Swedish subsidiary Boule Medical AB.

Number of shares

The number of shares and voting rights in Boule Diagnostics AB amounted to 4,707,138.

Personnel

The average number of employees in the Group in 2013 was 170 (162), of which the Parent Company accounted for 5 (4).

Distributed by country, the average number in Sweden was 73 (69), the US 73 (71), China 19 (19), Switzerland 3 (3), Poland 1 (0) and Mexico 1 (0).

The average number of women in the Group was 48 (47) and men 122 (115).

Accounting principles

This condensed year-end report for the Group has been prepared in accordance with IAS 34, Interim Financial Reporting, and the applicable provisions of the Annual Accounts Act. The accounting policies for the Group and the Parent Company are unchanged compared with those applied in the 2012 Annual Report.

For all financial assets and liabilities reported value is a good approximation of fair value.

The interim report for the parent company has been prepared in accordance with the Annual Accounts Act, chapter 9, on Interim Reports.

Consolidated statement of comprehensive income

SEK thousand	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012
Net sales	63,441	64,253	275,301
Cost of goods sold	-35,514	-36,002	-151,795
Gross profit	27,927	28,251	123,506
Other operating revenues	26	135	115
Selling and marketing expenses	-13,338	-11,522	-54,431
Administrative expenses	-7,477	-6,591	-25,148
Research and development expenses	-6,374	-4,768	-22,165
Other operating expenses	-266	-991	-1,527
Operating profit	498	4,514	20,350
Interest income	54	78	894
Interest expenses	-298	-61	-494
Exchange rate differences	-427	-166	-545
Net financial items	-671	-149	-145
Loss before tax	-173	4,365	20,205
Tax	-1,511	-2,229	-9,246
Net loss	-1,684	2,136	10,959
Other comprehensive income			
Items that may be allocated to net profit/loss			
Translation differences for the period from the translation of foreign operations	14	-3,043	-4,123
Total other comprehensive income/loss	14	-3,043	-4,123
Total comprehensive income for the period	-1,670	-907	6,836
Earnings/loss per share, SEK	-0.36	0.45	2.33

Consolidated statement of financial position

SEK thousand	31 Mar 2013	31 Mar 2012	31 Dec 2012
Assets			
Fixed assets			
Intangible assets			
Capitalized development expenses	81,358	49,132	73,879
Goodwill	61,588	62,297	61,584
Total intangible assets	142,946	111,429	135,463
Tangible fixed assets			
Plant and machinery	2,406	2,083	1,927
Equipment, tools and fixtures	11,987	10,140	12,168
Leasehold improvements	1,113	1,021	1,221
Total tangible fixed assets	15,506	13,244	15,316
Deferred tax assets	1,353	1,371	951
Total fixed assets	159,805	126,044	151,730
Current assets			
Inventories			
Raw materials and supplies	35,315	30,347	34,230
Intermediate goods	3,713	3,444	3,687
Finished goods and goods for resale	9,698	11,917	7,719
Total inventories	48,726	45,708	45,636
Current receivables			
Tax assets	1,096	928	1,643
Accounts receivable	46,149	37,518	50,974
Other receivables	7,607	6,774	7,237
Prepaid expenses and accrued income	4,049	2,862	2,140
Total current receivables	58,901	48,082	61,994
Cash and cash equivalents	15,815	21,158	15,871
Total current assets	123,442	114,948	123,501
Total assets	283,247	240,992	275,231

Consolidated statement of financial position (cont.)

SEK thousand	31 Mar 2013	31 Mar 2012	31 Dec 2012
Equity			
Share capital	4,707	4,707	4,707
Other paid-in capital	191,198	191,198	191,198
Translation reserve	-10,104	-9,038	-10,118
Retained earnings including net loss for the period	12,224	5,084	13,908
Total equity	198,025	191,951	199,695
Liabilities			
Long-term liabilities			
Long-term interest-bearing liabilities	716	618	717
Deferred tax liabilities	13,021	5,526	11,375
Total long-term liabilities	13,737	6,144	12,092
Current liabilities			
Current interest-bearing liabilities	27,787	4,443	20,195
Accounts payable	15,065	16,227	15,486
Tax liabilities	350	271	107
Other liabilities	3,821	2,338	3,991
Accrued liabilities and deferred income	23,962	19,118	23,165
Provisions	500	500	500
Total current liabilities	71,485	42,897	63,444
Total liabilities	85,222	49,041	75,536
Total equity and liabilities	283,247	240,992	275,231
Pledged assets and contingent liabilities			
Pledged assets	40,000	40,000	40,000
Contingent liabilities	Note 1	-	Note 1

Consolidated statement of changes of equity

SEK thousand	Share capital	Other contributed capital	Translation reserve	Retained earnings incl. profit/loss for the period	Total equity capital
Equity, opening balance, Jan. 1, 2012	4,707	191,198	-5,995	2,949	192,859
Comprehensive income/loss for the year					
Net profit/loss for the year			-	10,959	10 959
Other comprehensive income for the period			-4,123	-	-4,123
Comprehensive income/loss for the year			-4,123	10,959	6,836
Equity, closing balance, Dec. 31, 2012	4,707	191,198	-10,118	13,908	199,695
Equity, opening balance, Jan. 1, 2013	4,707	191,198	-10,118	13,908	199,695
Comprehensive income for the period					
Net loss for the period			-	-1,684	-1 684
Other comprehensive income for the period			14	-	14
Comprehensive income for the period			14	-1,684	-1,670
Equity, closing balance, March 31, 2013	4,707	191,198	-10,104	12,224	198,025

Consolidated cash flow statement

SEK thousand	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012
Operating activities			
Operating profit	498	4,514	20,350
Adjustments for items not included in cash flow 1)	1,034	1 715	5,053
Interest received	1	77	174
Interest paid	-299	-146	-495
Income tax paid	0	-925	-2,734
Cash flow from operating activities before changes in working capital	1,234	5,235	22,348
Cash flow from changes in working capital			
Increase (-) /Decrease (+) in inventories	-3,038	-3,078	-3,213
Increase (-) /Decrease (+) in operating receivables	2,760	5,446	-9,069
Increase (+) /Decrease (-) in operating liabilities	480	-4,735	882
Cash flow from operating activities	1,436	2,868	10,948
Investing activities			
Acquisitions of tangible fixed assets	-1,084	-1,937	-7,526
Disposal of tangible fixed assets	0	-	800
Divestment of associated companies	0	-	1,000
Retained development expenses	-7,563	-6,540	-31,287
Cash flow from investing activities	-8,647	-8,477	-37,013
Amortization of loans	0	-165	0
Increase (+)/Decrease (-) in current financial liabilities	7,165	-26,337	-11,361
Cash flow from financing activities	7,165	-26,502	-11,361
Cash flow for the period	-46	-32,111	-37,426
Cash and cash equivalents at the beginning of the period	15,871	53,701	53,701
Exchange-rate differences in cash and cash equivalents	-10	-432	-404
Cash and cash equivalents at the end of the year	15,815	21,158	15,871
1) Of which, depreciation and amortization	887	438	3,164

Parent company income statement

SEK thousand	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012
Net sales	1,829	2,058	10,020
Administrative expenses	-5,275	-4,676	-19,066
Other operating revenues	0	28	29
Other operating expenses	0	0	-6
Operating loss	-3,446	-2,590	-9,023
Result from financial items:			
Other interest income and similar income items	0	69	75
Interest expenses and similar expense items	-4	-2	-2
Loss before tax	-3,450	-2,523	-8,950
Tax	-	-	-
Net loss	-3,450	-2,523	-8,950

Parent Company statement of comprehensive income

SEK thousand	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012
Total comprehensive income	-3,450	-2,523	-8,950
Other comprehensive income for the period	-	-	-
Comprehensive income for the period	-3,450	-2,523	-8,950

Parent company balance sheet

SEK thousand	Mar 2013	Mar 2012	Dec 2012
Assets			
Fixed assets			
Tangible fixed assets			
Equipment	169	263	150
Total tangible fixed assets	169	263	150
Financial fixed assets			
Shares in Group companies	157,291	157,291	157,291
Total financial fixed assets	157,291	157,291	157,291
Total fixed assets	157,460	157,554	157,441
Current assets			
Current receivables			
Receivables from Group companies	40,395	42,978	44,977
Tax assets	-	206	174
Other receivables	1,099	2,032	213
Prepaid expenses and accrued income	617	437	300
Total current receivables	42,111	45,653	45,664
Cash and bank balances	772	6,162	438
Total current assets	42,883	51,815	46,102
Total assets	200,343	209,369	203,543
Equity and liabilities			
Equity			
Restricted equity			
Share capital (4,707,138 shares)	4,707	4,707	4,707
Statutory reserve	141 859	141 859	141 859
Unrestricted equity			
Share premium reserve	49,339	49,339	49,339
Retained earnings	1,740	10,689	10,690
Net loss for the period	-3,440	-2,523	-8,950
Total equity	194 195	204 071	197 645
Current liabilities			
Accounts payable	1,570	1,423	867
Liabilities to Group companies	-	229	-
Other liabilities	553	42	442
Accrued expenses and deferred income	4,025	3,604	4,589
Total current liabilities	6,148	5,298	5,898
Total liabilities	6,148	5,298	5,898
Total equity and liabilities	200,343	209,369	203,543
Pledged assets and contingent liabilities for the Parent Company			
Pledged assets	83,305	83,305	83,305
Contingent liabilities	Note 1	-	Note 1

	2013		2012			2011			
	Jan-Mar	Oct-Dec	Jul-Sep	Apr-Jun	Jan-Mar	Okt-Dec	Jul-Sep	Apr-Jun	Jan-Mar
Net sales, SEK million	63.4	76.3	63.8	71.0	64.3	67.7	57.7	57.6	63.2
Gross profit, SEK million	27.9	34.9	27.8	32.6	28.3	28.1	26.3	25.6	28.1
Gross margin, %	44.0	45.7	43.6	46.0	44.0	41.4	45.6	44.5	44.5
EBITDA, SEK million	1.4	6.9	2.9	8.8	5.0	4.9	6.3	2.2	6.7
EBITDA margin, %	2.2	9.0	4.5	12.4	7.8	7.2	10.9	3.8	10.6
Operating profit	0.5	6.0	1.5	8.3	4.5	4.2	5.5	1.4	6.0
Operating margin, %	0.8	7.9	2.4	11.7	7.0	6.3	9.6	2.5	9.5
Earnings/loss per share, SEK	-0.36	0.69	0.19	0.99	0.45	0.66	0.66	0.05	1.36
Cash flow from operating activities per share	0.31	-0.88	1.52	0.95	0.61	3.07	-1.81	0.45	-0.59
Return on equity, %	3.7	5.6	5.1	6.3	4.7	6.2	6.7	5.7	15.0
Equity per share, SEK	42.07	42.42	41.74	42.48	40.78	40.97	40.34	52.52	37.19

Definitioner

Gross profit is net sales less costs for goods sold

Gross margin is gross profit divided by net sales

EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is profit before net financial items, taxes and depreciation/amortization of tangible and intangible assets

EBITDA margin is EBITDA divided by net sales

EBIT (Earnings Before Interest and Taxes) is profit before net financial items and taxes.

EBIT margin is EBIT divided by net sales

Capital employed is total assets less deferred tax liabilities and non-interest-bearing liabilities

Working capital is inventories, accounts receivable and cash less accounts payable.

Net investments are investments in tangible and intangible assets adjusted for disposals

Interest coverage ratio is operating profit plus financial income divided by financial expenses

Net debt is interest-bearing assets less interest-bearing liabilities

Net debt/equity ratio is net debt divided by equity

Equity/assets ratio is equity divided by total assets

Return on equity is profit for the year after tax divided by average equity

Return on capital employed is profit after net financial items plus financial expenses divided by the average capital employed

Return on total capital is operating profit plus financial income divided by average total capital

Note 1 Contingent liabilities

The interpretation of the employment terms and conditions for two employees in the US subsidiary is subject to dispute. In Boule's opinion, there are no grounds to post a provision due to this matter.

For further information, please contact:

Ernst Westman

President and CEO
+46-8-744 77 00
ernst.westman@boule.se

Fredrik Alpsten

CFO
+46-8-744 77 00
fredrik.alpsten@boule.se

Stockholm, April 22, 2013

Boule Diagnostics AB

Lars-Olof Gustavsson
Chairman of the Board

Ernst Westman
President

Britta Dalunde
Member of the Board

Eva-Lotta Kraft
Member of the Board

Åke Nygren
Member of the Board

Gösta Oscarsson
Member of the Board

Audit review

This report was not reviewed by the company's auditors.

Calender

Interim report, second quarter _____ August 21, 2013
Interim report, third quarter _____ October 30, 2013

The Annual General Meeting will be held at Nalen, David Bagares Gata 17, at 6:00 p.m. on April 23, 2013.

The information in this interim report is such that Boule Diagnostics AB (publ) is obligated to publish under the Swedish Securities Market Act. The information was submitted for publication on April 23, 2013 at 8:00 a.m. (CET).

Boule Diagnostics AB (publ)

Box 42056
SE-126 13 Stockholm
Tel: +46 8-744 77 00
Corp. Reg. No.: 556535-0252
www.boule.se

